Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 subcutaneous guselkumab induction study in moderately to severely active ulcerative colitis
MOH_2023-01-11_012277Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in autoimmune colitis (3 arms), sponsored by Janssen Pharmaceutical. Started Dec 2022; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2023-01-11_012277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-11_012277.